Introduction
Childhood HIV infection and its consequences on development remain a significant public health issue in several countries. There are an estimated 2.3 million children under the age of 15 years living with HIV/AIDS in sub-Sahara Africa, with 330 000 in South Africa alone. A growing number of perinatally HIV-infected (PHIVþ) children in South Africa are surviving into adolescence, due to earlier diagnosis and initiation of effective antiretroviral therapies (ARTs). However, as elsewhere, PHIVþ adolescents face unique health issues, particularly related to neurocognitive and neurobiological complications resulting from HIV that will adversely hinder their transition into adult roles. HIV infection leads to changes in the structure and function of the central nervous system (CNS), which has significant consequences on academic performance and psychosocial functioning that compound over the lifespan [1] [2] [3] [4] . Recent data from our lab indicate a pattern of damaged neuronal microstructure, smaller gray matter volumes, reduced cortical surface area, and decreased gyrification in South Africa adolescents living with HIV and suggests abnormal neurodevelopment in perinatally infected adolescents [5] . The South African Department of Health first-line ART regimen for children older than 3 years and more than 10 kg is abacavir þ lamivudine þ efavirenz. First-line treatment failure may be a key factor associated with CNS damage in perinatally infected adolescents.
The complexity of the problem presents unique public health challenges, including how to identify those youths that are at risk for neurocognitive complications or who already have as-of-yet undetectable neurobiological aberrations due to HIV, and how to intervene effectively so that they can realize their full potential. Yet despite the obvious public health emergency this represents, the complex interaction these factors have on neurocognitive and neurophysiological functioning during this important life phase remain poorly understood. Indeed, recent findings that asymptomatic older PHIVþ children considered 'slow progressors' have measurable neurocognitive deficits that correlate with diffusion tensor imaging aberrations [6] is alarming. Therefore, it is important to understand the neurocognitive and neurodevelopmental issues in this group to assist in their transition to adulthood roles, and to open up avenues for helpful interventions.
Epigenetic regulation is an essential aspect of neurodevelopment and cell differentiation and is affected by environmental factors, thus making it a potent mechanism for understanding environmental effects on neurobehavioral and neurophysiological phenotypes [7] from early developmental aberrations into neurodegenerative diseases late in life [8, 9] . Because epigenetic mechanisms such as DNA methylation (DNAm) act as an interface between the environment and the genome, it is especially relevant when discussing neurocognitive problems in PHIVþ children, for whom a substantial environmental component is likely involved. We, and others, have shown that host DNAm is disrupted by HIV infection [10] [11] [12] [13] [14] . Specifically, we recently found evidence that HIV infection is associated with accelerated epigenetic aging based on the epigenetic clock [15] in both brain and peripheral blood mononuclear cells [10] . That is, brains of adults infected with HIV demonstrated age acceleration of 7.4 years compared with uninfected controls, and 5.2 years in peripheral blood mononuclear cells, findings that have been validated by other groups [12] [13] [14] . Furthermore, we have found that accelerated epigenetic aging can be observed in brain tissue samples of adults diagnosed premortem with HIV-associated neurocognitive disorders [16] . As such, the epigenetic clock method lends itself for detecting accelerated biological aging effects due to HIV infection in adult cohorts, and for determining whether accelerated epigenetic aging has significant health consequences. However, it is not yet known whether accelerated epigenetic aging effects are already detectable in adolescents and, if so, whether these epigenetic changes correlate with measures of cognitive performance, immune status, and ART treatment regimen.
In the current study, we apply the epigenetic clock to a cohort of South African adolescents to determine if perinatally acquired HIV infection is associated with accelerated aging in children and adolescents, and if so, whether or not it is also associated with neurocognitive impairment, current CD4
þ , viral load, and ART treatment line. Our hypotheses were that PHIV infection would be associated with accelerated aging, and that accelerated aging would be associated with neurocognitive impairment.
Materials and methods
This is a cross-sectional analysis of enrollment data from a substudy of the Cape Town Adolescent Antiretroviral Cohort (CTAAC), a longitudinal study of PHIVþ adolescents on ART in Cape Town, South Africa. The broader CTAAC study seeks to investigate markers of chronic disease processes and progression in five key areas (general adolescent development, neurocognitive function, pulmonary disease, cardiovascular function, and musculoskeletal disease) over a 48-month period. For the CTAAC substudy, PHIVþ adolescents were recruited from four routine ART services across Cape Town and were eligible to participate if they were aged 9-12 years, had been on ART for longer than 6 months, and knew their HIV-status. Controls were recruited from the same communities and schools attended by the adolescents living with HIV in an attempt to control for household income and quality of education. Controls were confirmed to be HIV negative, and were frequency matched to PHIVþ participants on age, sex, and ethnicity. Controls were excluded if they had known preexisting disease or if informed consent and assent was not obtainable. All youth screened for the control cohort underwent rapid HIV testing prior to enrollment to confirm negative status. Exclusion criteria for both groups were: an uncontrolled medical condition, such as diabetes mellitus, epilepsy, or tuberculosis (TB) requiring hospital admission; an identified CNS condition, including meningitis (TB or bacterial), cerebrovascular accident, lymphoma, history of head injury with loss of consciousness greater than 5 min or any radiological evidence of skull fracture, history of perinatal complications including hypoxic ischemic encephalopathy or neonatal jaundice requiring exchange transfusion, or neurodevelopmental disorder not attributed to HIV. All participants in the study completed neuroimaging studies, although these data are not presented here. A clinical neuroradiologist examined all the MRI scans to look for evidence of other secondary causes of CNS effects [including congenital infections such as cytomegalovirus (CMV)]. The primary caregiver of each adolescent provided written informed consent prior to participation, and child assent was obtained. Baseline health and sociodemographic questionnaires were administered to obtain general health information, past history and data on ancestry, and treatment. ART regimen (first/second/third line) and date of initiation of ART were abstracted from routine care records.
Neurocognitive functioning
Each participant completed a comprehensive neuropsychological test battery administered by trained research assistants in their home language. The neuropsychological test battery was comprised of a number of individual neuropsychological tests previously described in detail [17] . We conducted Cronbach's alpha tests on various combinations of neuropsychological tests to determine the statistical strength of each cognitive domain. Internal consistency was determined among the neuropsychological tests within each domain. The threshold for acceptable internal consistency was a Cronbach's a at least 0.7, which was found for general intellectual functioning, attention, working memory, visual memory, verbal memory, motor coordination, processing speed, and executive function. Composite cognitive domain scores were calculated by averaging the scores of the all tests that comprised each domain, so that a single score for each domain was determined for each participant. In addition, an overall cognitive impairment score was determined for each participant [17] .
Blood collection and processing
Blood samples were drawn at enrollment. DNA extraction from blood samples was accomplished using the QIAsymphony DSP DNA Midi kit and protocol. DNA was quantified using BioDrop (Whitehead Scientific, Cape Town, South Africa) and normalized to a concentration of 5-10 ng/ml. All samples were tracked using a Laboratory Information Management System (LIMS; Freezerworks, Seattle, Washington, USA).
DNA methylation
DNAm analysis was performed with the Illumina Infinium MethylationEPIC BeadChip (Illumina, San Diego, California, USA), which measures bisulfiteconversion-based, single-CpG resolution DNAm levels at 866 836 CpG sites in the human genome. The standard protocol of Illumina methylation assays quantifies methylation levels by the b value using the ratio of intensities between methylated (signal A) and unmethylated (signal B) alleles. Specifically, the b value is calculated from the intensity of the methylated (M corresponding to signal A) and unmethylated (U corresponding to signal B) alleles, as the ratio of fluorescent signals
Thus, b values range from 0 (completely unmethylated) to 1 (completely methylated) [18] . We used the noob normalization method [19] , which is implemented in the 'minfi' R package (https://www. r-project.org/) [20] .
DNA methylation age and the epigenetic clock Chronological age has been shown to have a profound effect on DNAm levels [21] [22] [23] [24] . As a result, several highly accurate epigenetic biomarkers of chronological age have been proposed [15, [25] [26] [27] [28] . These biomarkers use weighted averages of methylation levels at specific CpG sites to produce estimates of age (in units of years), referred to as 'DNA methylation age' (DNAm age) or 'epigenetic age'. Recent studies support the idea that these measures are at least passive biomarkers of biological age. For instance, the epigenetic age of blood has been found to be predictive of all-cause mortality [29] [30] [31] [32] , frailty [33] , lung cancer [34] , and cognitive and physical functioning [35] , whereas the blood of the offspring of Italian semisupercentenarians (i.e. participants aged 105 or older) was shown to have a lower epigenetic age than that of age-matched controls [36] . Further, the utility of the epigenetic clock method using various tissues and organs has been demonstrated in applications surrounding Alzheimer's disease [37] , centenarian status [36, 38] , development [39] , Down syndrome [40] , frailty [33] , HIV infection [10] , Huntington's disease [41] , obesity [42] , menopause [43] , osteoarthritis [44] , and Parkinson's disease [45] .
DNAm age (also referred to as epigenetic age) was calculated from human blood samples profiled with the Illumina Infinium EPIC array platform. We considered two different age estimators described in the following. First, we used the multitissue DNAm age estimator from Horvath [15] , which is defined as a prediction method of age based on the DNAm levels of 353 CpGs. Predicted age, referred to as DNAm age, correlates with chronological age in sorted cell types (CD4 þ T cells, monocytes, B cells, glial cells, neurons), tissues, and organs, including whole blood, brain, breast, kidney, liver, lung, saliva [15] . Second, we applied the Hannum measure of DNAm age based on 71 CpGs, which was developed using DNAm data from blood [27] .
Despite high correlations, epigenetic age estimates can deviate substantially from chronological age at the individual level. After adjusting DNAm age for chronological age, one arrives at measures of epigenetic age acceleration. Here we focus on two widely used measures of epigenetic age acceleration denoted by AgeAccelerationResidual and extrinsic epigenetic age acceleration (EEAA), respectively. By definition, both measures are independent of chronological age (at the time of blood draw). For both measures of age acceleration, positive (negative) values indicate that the blood sample is older (younger) than expected based on chronological age. The mathematical definition of these measures is briefly reviewed here. AgeAccelerationResidual is defined as the (raw) residual resulting from regressing the multitissue DNAm age estimate on chronological age. By definition, AgeAccelerationResidual is independent of chronological age. EEAA can be interpreted as an enhanced version of the Hannum measure of DNAm age estimator, because it up-weights the contributions of age-related blood cell counts [32, 46] .
In a recent large-scale meta-analysis involving over 13 thousand participants from 13 cohorts, we have shown that both AgeAccelerationResidual and EEAA are predictive of mortality, independent of chronological age, even after adjusting for additional risk factors, and within the racial/ethnic groups that we examined (whites, Hispanics, African Americans) [32] . The EEAA measure is attractive because it exhibited the strongest predictive association with all-cause mortality [32] and it revealed the strongest association with cognitive functioning measures in our study. AgeAccelerationResidual is attractive because it is less confounded by changes in blood cell composition, it applies to all tissue samples, and it is particularly accurate in adolescents, and we previously used it in our study of HIVþ adults [10, 15] .
Both AgeAccelerationResidual and EEAA were computed using the epigenetic clock software (http:// labs.genetics.ucla.edu/horvath/dnamage/) in which they are denoted as AgeAccelerationResidual and BioAge4HAStaticAdjAge, respectively.
Although AgeAccelerationResidual is relatively robust with respect to changes in blood cell composition, EEAA capitalizes on age-related changes in blood cell types and captures aspects of immunosenescence [32] .
The epigenetic clock method and software applies to data generated using any Illumina platform (including the EPIC array). Missing CpG probes were automatically imputed by the software. Mathematical details and software tutorials for the epigenetic clock can be found in the additional files of [15] . An online age calculator can be found at our webpage: http://labs.genetics.ucla.edu/ horvath/dnamage/. 
Statistical analyses

Results
Two hundred and four HIV-infected adolescents and 44 frequency-matched controls were enrolled. Demographic characteristics were similar between HIVþ adolescents and controls, Table 1 . HIV-infected adolescents were more likely to have had repeated grades at school (P ¼ 0.02). Most HIV-infected adolescents were on first-line ART (79.9%), with a mean CD4 þ cell count of 955 cells/ml, median viral load of less than level of detection copies/ml and mean age of initiation of ARTof 3.41 years. There were significant differences in cognitive ability between the two groups in the following domains: general intellectual functioning, executive functioning, attention, working memory, verbal memory, visual memory, visual spatial ability, language, and processing speed (Table 1) .
HIV-infected adolescents exhibit epigenetic age acceleration
The high accuracy of the epigenetic clock method is revealed by the surprisingly high correlation between DNAm age and chronological age (r ¼ 0.36, P ¼ 5.3E À 9) despite the narrow age range (adolescents are aged between 9 and 12 years). HIVþ adolescents exhibit increased levels of AgeAccelerationResidual and EEAA compared with HIV-controls (Fig. 1a and b) . Increased epigenetic age acceleration can even be observed in HIVþ individuals whose viral load is not detectable (viral load < 50 copies/ml).
We observe significant associations between HIV status and epigenetic age acceleration even after removing the 17 adolescents of mixed ancestry from the analysis (P ¼ 3.7E À 7 for AgeAccelerationResidual and P ¼ 1.4E À 6 for EEAA). EEAA and to a lesser extent AgeAccelerationResidual exhibit significant negative correlations with current CD4 þ T-cell counts in HIVþ adolescents.
Our analysis of ART line (first/second/third) (variable ARV.line) reveals that adolescents who are on second or third-line ART treatment are more likely to have accelerated aging (Fig. 1c and d) . Both AgeAccelerationResidual and EEAA remain significantly associated with current CD4 þ T-cell counts and ARV.line even after adjusting for viral load, educational status, ethnicity, and other potential confounders (Table 2) . Epigenetic age acceleration exhibits substantial heterogeneity in HIVþ adolescents. In HIVþ adolescents, age at ART initiation nor ART duration were significantly correlated with measures of epigenetic age acceleration nor with cognitive assessments. Similarly, household income was not correlated with epigenetic age acceleration in HIVþ adolescents. However, CD4 þ T-cell counts was negatively correlated with epigenetic age acceleration in HIVþ adolescents (Fig. 1) . A multivariate model analysis reveals that HIV viral load, current CD4 þ T-cell count, ethnicity, antiretroviral duration, ARV.line, and education explain only 8.8% of the variable in AgeAcceleration but 17.3% of the variation of EEAA in HIVþ adolescents (Table 2) .
Extrinsic epigenetic age acceleration relates to cognitive functioning measures We correlated both measures of epigenetic age acceleration with cognitive functioning measures but found significant correlations only for the extrinsic measure of epigenetic age acceleration: EEAA is significantly associated with overall cognitive impairment status (Fig. 2a) , and more specifically with the following cognitive domains: attention, working memory, executive functioning, and processing speed (Fig. 2b-e) . This association does not reflect confounding by HIV status, as we continue to observe significant associations between EEAA and working memory, executive functioning, and processing speed (Fig. 2f-i) after restricting the analysis to HIVþ individuals. These findings suggest that an epigenetically older immune system is associated with lower cognitive functioning. A multivariate linear model analysis reveals that both HIV infection and EEAA are independently associated with cognitive performance measures: executive functioning, working memory, and processing speed (Model 1 in Table 3 ).
Multivariate regression model analysis revealed that EEAA remained negatively associated with executive functioning (P ¼ 0.023), working memory (P ¼ 0.049), and processing speed (P ¼ 0.024) even after adjusting for HIV status, educational level (assessed by highest grade, and repeated grade), ethnicity, and household income.
Discussion
This is the first study to show that perinatally acquired HIV infection is associated with epigenetic age acceleration in blood, and extrinsic epigenetic age acceleration is associated with lower cognitive functioning in these adolescents.
We found significant differences between the HIVinfected participants and demographic-matched controls HIV accelerates epigenetic aging in adolescents Horvath et al. 1469 notably on tests of general intellectual functioning, visual spatial ability, visual memory, and semantic fluency (that is: executive functioning) [6] . Executive functioning emerges as one of the more prominent domains to be affected in this population. In a previous study conducted in Cape Town, HIV-infected youth were found to perform significantly poorer in executive function tasks, particularly in processing speed, cognitive flexibility, and inhibition [17] . Gaining insight into the factors contributing to cognitive impairment is essential, as subtle impairments may progress to more pronounced complications that will influence future intellectual performance, job opportunities, and community participation of HIV-infected youth. As with recent findings in HIVþ adults [16] , the current study suggests that epigenetic age acceleration may be a contributing factor to poorer cognitive function in adolescents living with HIV.
We previously reported ambiguous results regarding the correlation between HIV viral load and epigenetic age acceleration in HIVþ adults: although a positive correlation could be observed in one data set, it could not replicated in another [10] . In the current data set, we do not observe a significant association between viral load and epigenetic age acceleration in HIVþ adolescents which might reflect the low number of HIVþ individuals with detectable viral load (n ¼ 32). Our analysis of ART regimen reveals that adolescents who are on second or third-line ART treatment are more likely to have accelerated aging. Second-line ART, increased viral load, low CD4 þ cell counts, and poor cognitive function have been associated with poor white matter integrity in youth living with HIV in South Africa [48] . Although we have data on how many in the cohort have had to switch to second or third-line ART, we do not have adequate information as to why the switch had to occur. Whether this was due to side effects or virological failure is unknown.
Our study cannot exclude the possibility that the observed epigenetic aging effects in HIVþ adolescents reflect changes in cell composition, because our methylation data were generated from unfractionated blood. EEAA and AgeAccelerationResidual are highly correlated (r ¼ 0.59, P < 2.2E À 16), but these measures have different properties. By construction, EEAA relates to cell abundance measures that are known to change with age (e.g., naive CD8 þ T cells or conversely exhausted CD8 þ T cells). Further, EEAA exhibits stronger negative correlations with CD4 þ T-cell counts (r ¼ À0. 31 Fig. 1 ). EEAA is attractive as it captures aspects of immunosenescence, whereas AgeAccelerationResidual is attractive as it is less confounded by differences in cell composition [32, 49] . DNAm age of whole blood probably reflects properties of hematopoietic stem cells in the bone marrow because the majority of cells in whole blood are neutrophils and different blood cell types (neutrophils, B cells, T cells, monocytes) have roughly the same age [10] . Epigenetic age acceleration effects due to HIV have been observed in sorted blood cell [13] . Future research should carefully study which blood cell types exhibit cell intrinsic epigenetic age acceleration effects due to HIV infection.
One would perhaps not expect DNAm age of blood to be associated with measures of cognitive functioning in young adolescents. However, other studies in HIVuninfected older adults reported associations between epigenetic age acceleration of blood (based on the multitissue DNAm age) and white matter integrity in the brain [50, 51] and various measures of cognitive or memory functioning in older individuals [35, 52] .
Limitations of this study include the cross-sectional design, but longitudinal follow-up is underway to better understand the impact of epigenetic age acceleration on cognition in later adolescence. The control group is also small in comparison with the participant group but was nevertheless well matched. Although other congenital infections and incidental CNS abnormalities were excluded as far as possible on history, clinical examination, and on clinical review of the MRI scans, it remains a possibility that there may be some overlapping effects of undiagnosed conditions such as congenital CMV. A further limitation is the lack of objective measures of early life environmental exposures (e.g., psychological trauma) that may be more common in HIV-infected youths. Future research should focus on delineating specific factors that may account for accelerated aging in PHIVþ youth.
Conclusion
To our knowledge, this is the first cohort study to examine the impact of epigenetic age acceleration in adolescents living with HIV and the association with cognitive function. The study took place in South Africa, one of the countries most affected by HIV/AIDS with the highest rate of new HIV infections in the world. Despite a mean age of initiation of ART treatment of 3.4 years and usage for more than 7 years, considerable cognitive impairment is apparent. Longitudinal follow-up of our cohort will be crucial for determining the impact of epigenetic aging in adolescents living with HIV. Correlates of epigenetic aging need to be elucidated, including associations with measures of viral load, treatment duration, concurrent infections, and ART prescription and treatment adherence, to understand their impact on the long-term development of neurocognitive disorders in pediatric HIV. 
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